Updates are available Correction dated 2021-03-02
Click to view Correction: https://doi.org/10.1038/s41583-021-00447-7
-
Authors
- License Information
-
More Information
Article History
Accepted: 23 November 2020
First Online: 11 January 2021
Change Date: 2 March 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41583-021-00447-7
Competing interests
: H.A.L. has received funding from industry to support research on neurodegenerative diseases, including from Merck Serono, UCB and Abbvie. These companies had no specific role in the in the conceptualization and preparation of and decision to publish this work. H.A.L is also the co-founder and Chief Scientific Officer of ND BioSciences SA, a company that develops diagnostics and treatments for neurodegenerative diseases based on platforms that reproduce the complexity and diversity of proteins implicated in neurodegenerative diseases and their pathologies. M.B.F. is a co-founder of ND BioSciences SA and Director of Research and Development in the company. S.J. declares no competing interests.
